Implantation of the embryo into the maternal endometrium is the first step leading to placentation and ultimately ensures that the conceptus is provided with an adequate blood supply. The extent to which the conceptus invades the endometrium varies considerably among mammals, but in all species, considerable remodelling of the endometrium occurs at the site of implantation. The barriers breached to establish connections to the blood supply include the basement membranes of the uterine epithelium and the endothelium and, to a variable extent, the endometrial interstitial matrix supporting the stroma. The aggressiveness of trophoblast is otherwise only seen with malignant cells, and trophoblast invasion shares many of the features of tumour invasion and metastasis. The cardinal difference is that trophoblast invasion is tightly controlled whereas tumour invasion progresses without restraint. This review will examine the proteases likely to be involved in the implantation process, taking into account the interspecies differences. First, it will examine which proteases and specific inhibitors have been identified in the tissues associated with implantation, both in vivo and in vitro, and then review the functional studies that have given some indication of the relative importance of individual proteases. Finally, it will examine how these proteases might be regulated at a number of levels, including transcription, activation and inhibition.
Proteases, invasion and remodelling
Proteases with a role in extracellular matrix (ECM) degradation fall primarily into three categories: serine, cysteine and metalloproteinases (Barrett, 1994) . In addition, proteases that activate key regulatory molecules, such as tumour necrosis factor α (TNF-α), will play an important but undefined role in the events of implantation. Proteases thought to be important in implantation, along with their likely substrates, are listed (Table 1) . Moreover, as excessive or inappropriately timed proteolytic events need to be restrained, most known mammalian enzymes have partner protease inhibitors, which are often widely distributed in the same tissues in which the enzymes are likely to act.
Cysteine proteinases are lysosomal enzymes that act at acid pH. The best known are cathepsin B and cathepsin L, both of which cleave the N-terminal peptides of collagen that contain the covalent cross-links within and between molecules. Cathepsin B also cleaves the attachment region of proteoglycans to hyaluronan. Another member of this family, interleukin 1β-converting enzyme (ICE or caspase-1) (Tocci, 1997) , releases active interleukin 1β (IL-1β) from its precursor, providing this cytokine for local actions including the regulation of transcription of matrix metalloproteinases (MMP). Cysteine proteinases are controlled by members of the cystatin superfamily which include both intracellular (cystatin A and B) and extracellular (cystatin C) forms. The invasive phenotype of many metastatic cell types is associated with the increased production and secretion of cysteine proteinases and the aberrant regulation of cystatin C, and a role could be postulated for these molecules in embryo implantation.
Serine proteinases are the largest class of mammalian protease and most act at neutral pH. Among those produced in the uterus are urokinase-type plasminogen activator (uPA), plasmin (derived from plasminogen by the action of uPA), and kallikrein, which are produced mainly by endometrial fibroblasts, while enzymes such as mast cell tryptase, neutrophil elastase and granzyme are contained in specific migratory cells within the tissue and are released on activation. Many of these enzymes exert their action on matrix degradation, in part indirectly, by proteolytic activation of MMPs. Specific inhibitors, such as plasminogen activator inhibitor 1 (PAI-1), PAI-2 and protease nexin, which limit the action of PA, serve to balance the activity of many of these enzymes. Cell surface binding sites for uPA and plasminogen are present on cell membranes, often in the same cell and serve to focus the activity to the vicinity of the cell. Binding to these receptors enhances the proteolytic potential of the system markedly. Expression of uPA and PAIs is controlled mainly by transcriptional mechanisms, driven by hormones and growth factors in a cell typespecific manner. This PA-PAI-PAR-plasmin system (Fig. 1) is thought to be a key participant in the balance of matrix turnover (Vassalli et al., 1991) .
The third class of protease, the metalloproteinases, contains the most critical enzymes for matrix degradation and remodelling, the substrate activities of which collectively allow them to degrade virtually all the components of both interstitial matrix and basement membranes. The role of metalloproteinases in tumour invasion and metastasis is well-documented (Powell and Matrisian, 1996) . The best known grouping of these enzymes are the MMPs which fall broadly into four categories: the collagenases, gelatinases, stromelysins and membranetype MMPs. Most MMPs act extracellularly and at neutral pH and are released as latent precursors requiring activation by proteases such as plasmin, tryptase and elastase, as well as by other activated MMPs. MMPs can be regulated at a number of levels (Fig. 1) . Transcription is modified by growth factors, cytokines and steroid hormones, the actions of which are tissue-and cell-type specific and vary among the enzymes. Importantly in the present context, progesterone is a negative regulator of transcription of several MMPs including MMP-1, -3 and -9 (Salamonsen et al., 1997) , although this can be overridden by some cytokines, including IL-1 and TNF-α (Singer et al., 1997; Zhang et al., 1998) . Both transcriptional and posttranscriptional mechanisms regulate MMP and TIMP production; binding sites (AP-1 and PEA-3) for the transcription factors: fos and jun and Ets proteins, respectively, are present in the promoter regions of the genes (Crawford and Matrisian, 1996) , while a number of Ets proteins (Kilpatrick et al., 1998) , as well as fos and jun, are present in endometrium. The mechanisms by which MMP gene transcription is regulated in endometrium or trophoblast are not yet known. Most MMPs are secreted in their latent forms which require activation by proteolytic cleavage of the propeptide. Cascades of enzyme activation can be set up, as some MMPs, particularly MMP-3 and MMP-7, can activate others (Salamonsen and Woolley, 1996) . ProMMP-2 is unusual in that it is activated at the cell surface by the membrane type (MT)-MMPs (in the presence of tissue inhibitor of metalloproteinase 2 (TIMP-2)). Thus, the active form of this enzyme is associated closely with the cell membrane. Most studies on MMPs at implantation have localized either mRNA or immunoreactive protein in the tissue but have not produced evidence of activation. Once activated, MMPs are not necessarily available for tissue degradation, as a family of TIMPs act to restrain their action by binding their active forms with a 1:1 stoichiometry (Edwards et al., 1996) . Binding to α 2 -macroglobulin provides additional, but less specific, inhibition. At any focal point within a tissue, MMPcatalysed proteolysis of matrix will occur only if the active form of the MMP is present in molar excess over inhibitors.
Although proteolytic degradation of the ECM and the control of that action are the logical roles for MMPs and TIMPs, respectively, other functions described for these molecules may be important. Several MMPs degrade regulatory molecules, including IL-1β (Ito et al., 1996) , and insulin-like growth factor et al., 1994) , while MMP-7, an epithelial cell MMP, processes molecules such as TNF-α precursor and uPA (Wilson and Matrisian, 1996) . TIMP-1 and TIMP-2 have growth factor activities (Hayakawa et al., 1992 (Hayakawa et al., , 1994 and both embryotrophic (Satoh et al., 1994) and steroidogenic (Boujrad et al., 1995) actions have been described for TIMP-1, while TIMP-3 overexpression promotes apoptosis of vascular smooth muscle cells (Baker et al., 1998) . Whether any of these functions are important at implantation has not been established. Members of other metalloproteinase groups include enzymes such as TNF-α-converting enzyme (TACE) (Black et al., 1997) , a member of the adamalysin protease family that releases soluble TNF-α from its membrane-bound precursor and the action of which is inhibited by the same hydroxamic acid-based inhibitors that inactivate MMPs. Other adamalysins may also have actions to shed important cell-surface proteins.
Species differences in trophoblast invasion at implantation
Both the means by which the trophoblast penetrates the uterine epithelium and makes contact with the maternal blood supply and the extent to which the trophoblast invades the maternal endometrium vary considerably among species (Fig. 2) . Such differences must be taken into account in any discussion of trophoblast invasion. In rats and mice, which have haemochorial placentation, there is apoptosis of the uterine epithelium at the site of blastocyst apposition (Parr et al., 1987) before the trophoblast invades the stroma. Originally it was assumed that the initial breaching of the epithelium and its basement membrane resulted from the invasive nature of the trophoblast but, subsequently, it was shown that, in normally implanting rats and mice, the basement membrane is first perforated by decidual cells alone (Schlafke et al., 1985; Blankenship and Given, 1991) . Decidual cells also penetrate the basement membranes of stromal vasculature but these are eventually replaced by trophoblast (Welsh and Enders, 1987) . In primates, including humans, the cytoplasmic protrusions of trophoblast interdigitate between the uterine epithelial cells and spread along the basement membrane underlying the luminal epithelium, before eroding this and invading into and through the stroma, eventually to tap the blood vessels (Enders, 1997) . The human trophoblast is highly invasive in vivo and can penetrate the full thickness of the endometrium, reaching as far as the first third of the myometrium. By contrast, even in closely related primates, invasion is limited to the endometrium (Ramsey et al., 1976) , suggesting either particularly invasive trophoblast or less efficient inhibition of invasion in humans.
In ruminants such as sheep and cattle, in which placentation is synepitheliochorial, the trophoblast does not invade through the uterine epithelium into the uterine stroma, although there is considerable tissue remodelling and development of new blood vessels. At implantation, fetal chorionic binucleate cells fuse with those of the uterine epithelium and the syncytial cells penetrate through the basal lamina (Wooding and Flint, 1994) . In other species with epitheliochorial placentation (for example, pigs), there is also little direct invasion of the trophoblast into the uterine stroma. Horses appear to be unique in that they have a subpopulation of highly invasive trophoblast cells forming the chorionic girdle that become highly invasive around day 35 of pregnancy, penetrating through the uterine epithelium into the stroma to form endometrial cups (Enders and Liu, 1991) .
Trophoblast cells from most species appear to have a high degree of invasive capacity that can be demonstrated outside the uterine lumen or in vitro. Human trophoblast can invade at any of a number of extrauterine sites, as evidenced by the number of ectopic pregnancies in women, while mouse trophoblast penetrates basement membrane derived from the uterine epithelium in vitro (Armant and Kameda, 1994) and, in vivo, when transplanted to an ectopic site, invades uncontrollably (Enders et al., 1981) . Even pig trophoblast can penetrate nonuterine epithelia and develop in ectopic sites (Samuel and Perry, 1972) . However, within the microenvironment of the uterus, trophoblast invasion is strictly limited. Both the hostility of the uterine epithelium to a conceptus, apart from during the 'window of implantation', and the presence of protease inhibitors probably restrain the movement of this very invasive tissue, with the level of restraint varying with the type of placentation.
In spite of these differences, as some of the molecular events resulting in the establishment of pregnancy have come to be understood, it has become apparent that the molecules involved in trophoblast invasion are highly conserved among species (Nie et al., 1997) .
Expression patterns of proteases at implantation sites
It has long been suspected that proteolytic enzymes play a role in trophoblast invasion. Strickland (1976) showed that uPA was produced by mouse trophoblast, that this coincided with the invasive phase of the embryo and that it was localized to regions of the invasion. Roles for both MMPs and cathepsins have also been suggested and a number of proteases and inhibitors are produced by the conceptus and the endometrium of all species examined ( Table 2 ). The present discussion will focus primarily on the early phases of trophoblast invasion rather than on the subsequent events of placental development.
Species with haemochorial implantation
Mouse. Cathepsin B mRNA is expressed by mouse trophoblast throughout the invasive period (days 5.5-10.5) and the proteins for cathepsins B and L are localized to the mature invasive trophoblast giant cells; the activity of these enzymes has also been demonstrated. Cathepsin L is also present within the stroma, particularly in the lateral decidualizing zone. Cystatin C, the major inhibitor of cathepsins, is a major product of the adjacent decidualizing stroma close to the embryo, suggesting a restraining role. After the completion of placental trophoblast invasion (day 11.5), the trophoblast cells express high concentrations of cystatin C, probably in association with a switch from an invasive cell type to one providing nutrients to the conceptus (Alfonso et al., 1997) .
There is also a very distinct and cell-specific expression pattern of the type IV collagenases, MMP-2 and MMP-9, and TIMP-1, -2 and -3, during mouse embryo implantation (Reponen et al., 1995; Alexander et al., 1996; Leco et al., 1996; Das et al., 1997) . In particular, MMP-9 is expressed weakly at 4.5 days of gestation (day 0 = day of plug) with mRNA present in some rounded trophoblast cells, increasing to intense expression in the multinucleated trophoblast giant cells emerging around the embryo and penetrating the uterine surface at day 5.5. On days 6.5-8.5, MMP-9 mRNA is observed in numerous trophoblast giant cells surrounding the embryo and invading the uterine stroma. In the uterus, MMP-9 mRNA is induced in some stromal cells on day 4, at the time of blastocyst apposition but then disappears (Das et al., 1997) . Expression of MMP-2 differs significantly from that of MMP-9. Its mRNA is not detected in embryonic or extra-embryonic tissues but a positive reaction is seen in uterine mucosal stroma cells outside the decidualized area (Reponen et al., 1995; Das et al., 1997) . While no TIMP-1 or -2 expression is observed in the embryo, trophoblasts or decidua, intense TIMP-3 mRNA is present in maternal cells in the area of the decidual reaction surrounding the 5.5 day early egg cylinder, and this reduces considerably by day 7.5 (Reponen et al., 1995; Alexander et al., 1996; Leco et al., 1996) . The strong expression of MMP-9 in the trophoblast at days 4.5-7.5, and of TIMP-3 in the surrounding decidua, but their reduction during the same time interval implies a crucial role for each in the implantation-invasion process (Reponen et al., 1995) . At present, there is little information on how TIMP-3 and MMP-9 expression is regulated directly or indirectly at implantation sites in vivo, although in vitro studies implicate leukaemia inhibitory factor (LIF) and epidermal growth factor (EGF) (Harvey et al., 1995) . MMP-13 (mouse collagenase) does not seem to participate in the implantation process and MMP-3 is found primarily in the myometrium with no change in expression during peri-implantation (Das et al., 1997) . Uterine concentrations of TIMP-1 and -2 also do not change.
Components of the urokinase system are also expressed in a finely regulated pattern during mouse implantation (Teesalu et al., 1996) . A high abundance of uPA mRNA is found in invasive trophoblast cells, which do not express PAI-1. Urokinasetype PA is also expressed in the endothelial cells of newly forming vessels from day 6.5. The uPA receptor and the low density lipoprotein receptor-related gene (LRP) are expressed by decidual tissue and co-localize with uPA and PAI-1, a finding of particular interest in view of the role of the two receptors in clearing uPA-PAI-1 complexes. Active uPA has been demonstrated in the ectoplacental cone region at days 7.5-8.5.
Thus, all classes of protease associated with degradation of extracellular matrix are expressed in a temporal and cellspecific pattern consistent with their likely roles in the invasive process of implantation in the mouse. Furthermore, these expression patterns are matched by those of specific inhibitors in the tissue surrounding the site of invasion.
Primates, including humans. Data localizing proteases or their inhibitors at early implantation sites in primates are not available at present, although information gleaned from in vitro studies (see below) suggest that there will be many similarities with the data from rats and mice. Between 6 and 40 days after attachment in macaques, MMP-1, -2 and -9, but not cathepsin B or D, are seen within intraluminal and intramural cytotrophoblast, although the cathepsins are present in uterine macrophages and stromal cells. MMP-2 has been immunolocalized in many different cell types, including all types of trophoblastic cells, decidual cells, Hofbauer's cells and villous fibroblasts within human implantation sites during the first trimester (Fernandez et al., 1992) .
During the secretory phase of the normal menstrual cycle, MMP protein is not detectable by immunohistochemistry in the endometrial stroma. MMP-9 is immunolocalized within the luminal and glandular epithelium during the postovulatory period and can be seen progressing towards the apical surface of the cells, being released into the uterine lumen just at the time the surface becomes receptive (Jeziorska et al., 1996) . The role of MMP-9 at this time is not yet understood but it may cleave components of the glycocalyx. MT1-MMP is also detectable in endometrial epithelium from day 20 of the normal cycle (J. Zhang and L. Salamonsen, unpublished) and it is postulated that this activates MMP-2 of conceptus origin in a fertile cycle, facilitating penetration of the epithelial basement membrane. TIMP-1, -2 and -3 are present in human endometrium across the cycle in all cellular compartments (Zhang and Salamonsen, 1997) and are strongly expressed in decidual cells late in the cycle. These inhibitors would provide a substantial barrier to invasion.
Endometrial leukocytes are an additional source of both enzymes and regulatory molecules that may modify enzyme production by adjacent cells. In mid-luteal phase human endometrium, these are primarily macrophages, neutrophils, large granular lymphocytes and mast cells (see Salamonsen and Woolley, 1996) . Activation of mast cells in normal human endometrium has been observed around day 20 of the cycle (Jeziorska et al., 1995) . Mast cell tryptase cleaves collagen VI (Kielty et al., 1993) and, thus, is likely to contribute to the preparation of the stromal matrix for implantation in humans. Mast cell tryptase is also capable of establishing a cascade of MMP activation by its initial cleavage of the propeptide from proMMP-3 (Salamonsen and Woolley, 1996) . The role of endometrial leukocytes during placentation in women has been reviewed (Loke and King, 1995 (Hofmann et al., 1994) . Whether these factors are important at earlier stages of the implantation process remains to be determined.
Species with epitheliochorial placentation
Uterine flushings from pregnant ewes at the time of implantation contain MMP-2 and MMP-9, and these have been immunolocalized in trophoblast on day 17 and detected in media after trophoblast culture (Salamonsen et al., 1995) . Periimplantation pig embryos produce uPA and MMP-2 and -9 (Mullins et al., 1980; Fazleabas et al., 1983; Menino et al., 1997) , although the MMPs are not detectable by immunohistochemistry, suggesting low expression (Menino et al., 1997) . In sheep and pigs, a variety of protease inhibitors, including PAI and TIMPs, are produced both by the trophectoderm (Menino et al., 1997) and the endometrium (Salamonsen et al., 1995) and probably limit the invasive activity of the conceptus (Roberts et al., 1993; Salamonsen et al., 1995; Menino et al., 1997) . The endometrium of these species also has the potential to produce a range of MMPs (Salamonsen et al., 1995) , and their focal production is doubtless important for the extensive vascular changes associated with implantation.
Several lysosomal enzymes, including cathepsins B1, D and E and leucine aminopeptidase (see Roberts and Bazer, 1988) , are also synthesized and released into the uterine lumen by the endometria of species that display non-invasive epitheliochorial types of implantation. A cathepsin L-type polypeptide in the endometrium and in uterine flushings of gilts appears to be regulated by progesterone. Its concentration increases markedly during the attachment phase and it may assist with placental attachment through the limited proteolysis of the glycocalyx on the maternal epithelium and trophoblast (Geisert et al., 1997) .
Production of proteases by components of the embryo-maternal axis in vitro

Functional studies in vitro
Mouse trophoblast produces proteolytic enzymes in vitro. Outgrowths from cultured mouse blastocysts release components from subjacent radiolabelled ECM after attachment (Glass et al., 1983) and, when cultured with an ECM purified from mouse endometrium on day 4 of pregnancy, this trophoblast migrates through the matrix in a manner resembling trophoblast invasion in vivo (Armant and Kameda, 1994) . This migration is associated with the production of proteolytic enzymes, including MMP-9 (Behrendtsen et al., 1992) . Although these data appear to be at odds with the observations that decidual cells are the first cell type to breach the basement membrane, clearly neither the restraining influences nor the normal regulatory controls of gene expression and enzyme activation are present in the in vitro environment. Both TIMP-1 (Behrendtsen et al., 1992) and inhibitors of cysteine proteinases (Barbiarz et al., 1992) prevent mouse trophoblast invasion in vitro, suggesting that at least two protease families are involved in the invasion.
Preimplantation human embryos, collected as oocytes after superovulation and cultured until the 32-cell stage, display collagen IV-degrading enzyme activity. The secretion of the enzyme(s) increases with time in culture, suggesting an increasing capacity for invasion. The enzyme activity produced per cell is up to 60 000 times greater than that produced by a normal fibroblast (Puistola et al., 1989) . Studies on the invasiveness of human trophoblast have used cytotrophoblast cells of first trimester pregnancy to study implantation, applying the rationale that these cells retain almost all the properties of the trophectodermal cells of the blastocyst. Once attached to a thick layer of ECM, these trophoblasts invade it (Fisher et al., 1989; Shimonovitz et al., 1994) . They secrete several gelatindegrading proteases, particularly proMMP-9 and proMMP-2 (Fisher et al., 1989; Bischof et al., 1991; Librach et al., 1991) , and these activities can be abolished by inhibitors of metalloproteinases but not by inhibitors of other types of proteases (Fisher et al., 1989; Bischof et al., 1991) . In contrast, trophoblastic vesicles derived in vitro from marmoset monkey trophoblast, released predominantly MMP-2 when cultured on laminin and fibronectin, suggesting that, if MMP-9 is necessary for trophoblast invasion, then the appropriate stimulatory factors were not present under the culture conditions used (Franek et al., 1997) . Human endometrial fibroblasts are the major endometrial source of a number of MMPs, including MMP-3 (Salamonsen and Woolley, 1996) . Co-culture of such cells with human cytotrophoblasts in a system where direct contact between the cells did not occur, inhibited the production of MMP-3 by the fibroblasts. This inhibition appeared to be tissue-specific, as similar inhibition did not occur when the fibroblasts were derived from skin. Such inhibition, if it occurs in vivo, may provide a mechanism by which invasion is arrested during trophoblast cell migration (Bellingard et al., 1996) . Neutralizing antibodies against MMP-9 inhibit ECM degradation by both mouse blastocyst outgrowths and human cytotrophoblasts in vitro, suggesting that MMP-9 is the common effector of trophoblast invasion (Librach et al., 1991; Behrendtsen et al., 1992) in these two species in which implantation is highly invasive.
Trophoblast-derived proteases have been identified in vitro in species with epitheliochorial placentation. MMPs are produced by ovine trophoblast in culture: latent and active forms of MMP-2 and -9 have been identified, although no proteases that are active against casein (including MMP-1 and MMP-3 along with a number of serine proteases) can be detected. Similarly, trophoblast cells from the equine chorionic girdle have matrix-degrading activities and produce both MMP-2 and MMP-9 when cultured on the artificial basement membrane, Matrigel (Vagoni et al., 1995) . This invasion was inhibited by 1,10,phenanthroline, a specific inhibitor of MMPs, but not by aprotinin and bestatin, which inhibit serine proteases and amino peptidase, respectively.
Thus, essentially the same proteases and inhibitors are associated with implantation in all species, regardless of the extent of invasion, the exception being that MMP-2 appears not to be a trophoblast product in mice. In other species, MMP-2 is produced by trophoblast in vitro and is detectable in the uterine lumen during early implantation. Whether MMP-2 and MMP-9 are both activated at implantation sites remains to be determined.
Functional studies in vivo
Strategies to establish whether proteases are critical for implantation include treatment with specific synthetic protease inhibitors during early pregnancy, immunoneutralization of protease action and examination of reproductive function in genetically modified mice (Table 3) . Such experiments have provided some in vivo support to the concept that proteases are important for implantation, although, in general, interference with protease production or activity has not resulted in a reduction in live births.
Studies in mice that are deficient in individual MMPs have provided a diversity of results. Mice with a mutated MMP-7 gene (Rudolph-Owen et al., 1997) have no evidence of significant reproductive dysfunction, in that they are fertile and can produce multiple litters. MMP-7 has been associated with the involution of the rat uterus (Sellers and Woessner, 1980) and is also present in human endometrial epithelium, although a role in implantation has yet to be established. MMP-3-deficient mice (Rudolph-Owen et al., 1997) have no obvious defect in reproductive function as determined by the average litter size. In both these groups of mice, no deficiencies in the expression of other MMPs were observed. It is possible that there is compensation for the loss of one MMP family member by overexpression of other family members: this is an artefact of the mechanism used for targeted gene deletion. Alternatively, active MMPs may trigger a pathway that represses the expression of other MMPs with similar substrates, to control the extent of matrix degradation, and this negative feedback loop may be disrupted in the MMP-targeted mice.
Given that MMP-9 is a major product of invasive trophoblast, it might be expected that specific disruption of its gene, or inhibition of its action, would severely disrupt trophoblast invasion. Neither targeted disruption of the MMP-9 gene (Alexander et al., 1996) nor overexpression of the gene for TIMP-1 (Rinkenberger et al., 1997) resulted in a decrease in the number of live births, although both affected the extent of decidualization at implantation sites and resulted in misorientation of embryos. Targeted deletion of the conserved DNA-binding domain of the Ets2 transcription factor, which results in deficient expression of MMP-9, did not actually block implantation per se, but did result in the retardation and death of homozygous embryos (Yamamoto et al., 1998) . Similarly, injection of MMP inhibitors, including MPI (Alexander et al., 1996) and doxycycline (L. Salamonsen and M. Rechtman, unpublished), into pregnant mice and rats, respectively, before implantation, did not block the implantation process, although both treatments slowed the development and remodelling of the decidual zone; the width and length of this zone was reduced in treated mice. In spite of the apparent defects in decidualization, all animals were fertile and did not exhibit increased embryo resorption (Alexander et al., 1996; Rinkenberger et al., 1997) or numbers of implantation sites on day 7 (L. Salamonsen and M. Rechtman, unpublished). However, these data do suggest that MMPs facilitate decidual morphogenesis and development.
Injection of E64, a synthetic inhibitor of cathepsin B and L, into pregnant females at the stage of blastocyst attachment, resulted in complete failure of implantation at high doses and in stunted embryo development and reduced decidual reaction at lower doses (Alfonso et al., 1997) . Like the MMPs, these cathepsins are necessary for uterine decidualization, and have an additional role in normal embryo development. In contrast with the MMPs and the cathepsins, the plasminogen activators do not appear to be essential for mouse development or fertility. Mice with combined deficiency of tissue-type PA (tPA) and uPA survived embryonic development, with both single-and double-deficient mice appearing normal at birth (Carmeliet et al., 1994 (Carmeliet et al., , 1995 . Similarly, disruption of the gene encoding uPA receptor, which focuses plasmin-mediated pericellular proteolysis and clears uPA-inhibitor complexes from the cell surface (Bugge et al., 1995) , did not affect development or reproduction, including implantation. Furthermore, targeted inactivation of α 2 -macroglobulin does not affect fertility in homozygous animals (Umans et al., 1995) .
Partial functional overlap with regard to both sites of expression and substrate specificity probably explains why loss or inhibition of any one component does not necessarily compromise overall extracellular matrix remodelling or turnover. The interplay between the various protease systems could perhaps be better understood by the application of combinations of inhibitors of the various protease classes.
Regulation of protease activity at implantation
Proteases (for example, the matrix metalloproteinases: Fig. 1) can be regulated at a number of levels, including transcription, stability of the mRNA, activation and inhibition. From the data currently available, it is likely that most, if not all, of these mechanisms are used at implantation.
Regulation of transcription
Many cytokines, growth factors and steroid hormones have been implicated in the regulation of proteases, in a range of cell types. Some control endometrial or trophoblast proteases and inhibitors in vitro. Given the diversity of the known regulators, a high degree of overlap in their functions is likely and few appear to be essential for blastocyst implantation. Leukaemia inhibitory factor (LIF) regulates mouse trophoblast MMP-9 and uPA expression in vitro (Harvey et al., 1995) , and maternal LIF, produced by the luminal epithelium at implantation, is critical for implantation in mice, although not necessarily in other species (Stewart et al., 1992; Vogiagis et al., 1997) . Given that MMP-9-deficient mice were able to carry litters to term, it is likely that LIF has additional, as yet undefined roles at implantation. The cytokine, IL-1β, found in both mouse and human uterus during the pre-implantation stages of development (Simon et al., 1993; Kover et al., 1995) is activated by a serine protease, ICE (Tocci 1997) , and is a potent regulator of MMP production by endometrial cells and cytotrophoblast (Librach et al., 1994; Salamonsen and Woolley, 1996) . Injection of IL-1 receptor antagonist into mice blocked implantation (Simon et al., 1994) ; however, in contradiction, deletion of the type 1 IL-1 receptor protein resulted in homozygous females that were fertile (Abbondanzo et al., 1996) . As with LIF, IL-1 is likely to have additional functions associated with implantation. It is also possible that another cytokine, such as TNF-α, compensates for the IL-1 deficiency. However, mice that are doubly deficient for both IL-1 receptor and the TNF-p55 receptor are also fertile (cited in Abbondanzo et al., 1996) .
Transforming growth factor β (TGFβ) promotes the deposition of ECM and inhibits the production of MMPs. TGFβ is also a potent inducer of TIMP-1 and TIMP-2 (Graham et al., 1994) and may be a negative regulator of trophoblast invasion (Cross et al., 1994) . The literature concerning cell-specific and temporal patterns of TGFβ1, -2 and -3 expression in the uterine endometrium during the oestrous cycle and early pregnancy and in the developing embryo has been reviewed (Godkin and Dore, 1998) . Although the TGFβ proteins are widespread, production of active forms requires protease cleavage (by mechanisms not yet understood) and this may control TGF action at focal points. Decidual cells may limit invasion by loading latent TGFβ into the ECM (Das et al., 1997) . As trophoblast invades, plasmin generated via cell surface uPA may trigger the activation of latent TGFβ, increasing TIMP expression and helping to terminate the invasion process.
The attachment of cells to ECM molecules via cell-surface receptors also regulates protease transcription. In particular, attachment to laminin or fibronectin is considered to be required for the traction and stabilization of migrating cells as well as for inducing MMP expression (Stetler-Stevenson et al., 1993) . Cell mobility may also be induced by hyaluronan (Goshen et al., 1996) , which is widely distributed in human endometrium in the mid-luteal phase (R. Stern and L. Salamonsen, unpublished) and in mouse uterus at implantation sites (Brown and Papaioannou, 1992) . In primates, in which the trophoblast does not immediately invade the basal lamina underlying the luminal epithelium, it is likely that components of this ECM play a role in regulating MMP production.
Activation of enzymes
The invasive capacity of trophoblast is restricted to the fetomaternal interface in a temporally defined manner, suggesting that the activation of proteases is a control mechanism. There are mechanisms to account for the focal activation of trophoblast proMMP-2 and proMMP-9 (Fig. 1) . In other systems, proMMP-2 activation occurs in association with the plasma membrane by the action of the MT-MMPs. The role of the MT-MMPs in trophoblast invasion has not yet been defined. However, MT1-MMP is expressed in the luminal epithelium of human endometrium mid-cycle, at a time corresponding to the window of receptivity, and may function to activate proMMP-2 on the trophoblast cell surface at the basal lamina (J. Zhang and L. Salamonsen, unpublished). MT1-MMP has also been localized in early human placenta and in decidual membrane (Hurskainen et al., 1998) . Studies in vitro have not demonstrated active MMP-2 in cytotrophoblast cultures and support its likely activation in vivo by endometrial MT-MMPs. MMP-9 activity may also be focused at the plasma membrane by activation through the PA system. Although pro-uPA is secreted as a soluble protein, it binds to a specific cell-surface receptor. The uPA can convert the plasminogen that is abundant in most extracellular fluids to plasmin, a protease of broad specificity that activates proMMPs, including MMP-9, although, at present, the mechanisms controlling the activators are not understood. In addition, human chorionic gonadotrophin (hCG), an important product of both cytotrophoblast and trophectodermal cells, downregulates MMP-9 and uPA activities in first trimester cytotrophoblast and this downregulation is associated with decreased invasion in vitro (Yagel et al., 1993) . Since the mRNA for MMP-9 is not affected, it can be postulated that hCG, via its action on uPA, limits the conversion of latent MMP-9 to its active form and, thus, regulates the transient invasive activity of the trophoblast.
Role of protease inhibitors
Why do carcinoma cells invade uncontrollably while trophoblast invasion is restrained? The evidence suggests that trophoblast invasion is controlled because the cells of the uterus produce particularly large quantities of specific inhibitors, which provide a protective function. In species with interstitial implantation, the decidual cells probably play an important role. In mice, these cells produce large quantities of TIMP-3 from day 5.5 to day 7.5 (Alexander et al., 1996; Leco et al., 1996) while, in humans, decidual cells express TIMP-1, -2 and -3 during the late luteal phase of the cycle (Zhang and Salamonsen, 1997). Cystatin C (Alfonso et al., 1997) and PAI (Hofmann et al., 1994; Teesalu et al., 1996) are also appropriately present near implantation sites in these species. In both pigs and sheep, TIMPs and PAI are present in the endometrium at implantation, even though decidualization does not occur (Mullins et al., 1980; Hampton et al., 1995; Menino et al., 1997) . Broad spectrum protease inhibitors, such as α 2 -macroglobulin, probably also assist in inhibiting trophoblast invasion.
Conclusions
Matrix-degrading proteases, and enzymes that activate either the proteases or regulators of their activation pathways, have an undisputed role in the early stages of embryo implantation, particularly with respect to invasion of the trophoblast. However, no one protease, or even one class of protease appears to be solely responsible for the invasion. The contribution of various inhibitors to restraining this trophoblast invasion is also without doubt. Indeed, the difference between mammalian species in the extent of invasion is likely to be attributable to such inhibitors. The major differences between tumour invasion and invasion of the trophoblast appear to be, first, the restraint imposed by endometrial inhibitors, and second, that trophoblast does not induce MMP production in adjacent cells of the host tissue as is seen with tumour invasion.
Given the centrality of the process of implantation to the continuation of mammalian survival, the evolution of a myriad of redundant and compensatory mechanisms to maintain reproductive capacity provides important safeguards. It is not surprising that the manipulation of genes for single proteases or inhibitors has not caused the failure of implantation, given the complexity of the pathways controlling the expression, activity and inhibition of the proteases and the expression of their inhibitors, together with the overlapping substrate specificities and redundancy in regulatory molecules.
The identities and roles of other proteases at implantation sites remain to be determined. However, it is becoming apparent that proteases with additional roles not necessarily related to matrix degradation will also be of importance to the implantation process.
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